Abstract | BACKGROUND: METHOD: RESULTS: Seventy-eight patients met the inclusion criteria (51 women), ages ranging from 16 to 76 years old (mean=42.2). Dosage of clobazam ranged from 5 to 60 mg/day (mean=22.6 mg/day). Clobazam was used from one month to eight years (mean=29 months). Sixteen (20.5%) patients were seizure-free, 20 (25.5%) had more than 75% improvement in seizure control, eight (10%) had more than 50% and 20 (26%) were non responders to clobazam. In 14 (18%) we could not determine seizure frequency during follow-up. The improvement in seizure control lasted for more than one year in 30 (68%) patients. CONCLUSION:
|
Authors | Maria Augusta Montenegro, Claudio Meilman Ferreira, Fernando Cendes, Li M Li, Carlos A M Guerreiro |
Journal | The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
(Can J Neurol Sci)
Vol. 32
Issue 1
Pg. 93-6
(Feb 2005)
ISSN: 0317-1671 [Print] England |
PMID | 15825553
(Publication Type: Journal Article)
|
Chemical References |
- Anticonvulsants
- Benzodiazepines
- Clobazam
|
Topics |
- Adolescent
- Adult
- Aged
- Anticonvulsants
(therapeutic use)
- Benzodiazepines
(therapeutic use)
- Clobazam
- Drug Therapy, Combination
- Epilepsy, Temporal Lobe
(drug therapy)
- Female
- Hippocampus
(pathology)
- Humans
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Retrospective Studies
- Sclerosis
(drug therapy, pathology)
|